Effect of External Counter Pulsation on Coronary Artery Disease
Unknown statusPhase 3NCT03075124
View the official record on ClinicalTrials.gov Recruiting status changes often. Contact the study team listed on ClinicalTrials.gov, and talk to your doctor before joining a study.
This study has no listed site in Canada in this snapshot. It is included as part of the worldwide chronic pain corpus.
Brief summary (from the registry)
Coronary artery disease (CAD) is prevalent worldwide and the leading cause of mortality of citizens, external counter pulsation (ECP) has been elucidated that it may release angina symptoms and improve the prognosis of CAD, however, no multi-center control clinical study has been reported for further recommendation. The aim of this study is to evaluate the effect of ECP on CAD. To address this assumption, investigators enroll participants with stable CAD and randomize them into control or ECP group, the ECP intervention will be carried out with a standard protocol which involves 35 one-hour sessions (5 days a week) for continuous 7 weeks, and the follow-up will last for 1 year. The primary endpoint is the 1-year composite cardiovascular events (CCE), secondary endpoints include frequency of angina pectoris, heart function, biomarkers of arteriosclerosis, exercise tolerance and endothelial function.
Study details
- Official title
- Effect of External Counter Pulsation on Coronary Artery Disease (ECP-CAD)
- Interventions
- Device: External Counter Pulsation
- Sponsor
- Eighth Affiliated Hospital, Sun Yat-sen University
- Collaborators
- Second Affiliated Hospital of Xi'an Jiaotong University; Second Affiliated Hospital of Zhengzhou University; Shanghai 10th People's Hospital; Xiangya Hospital of Central South University
- Start date
- 2018-06-08
- Primary completion
- 2019-05-28
- Sex
- All
- Age range
- from 18 Years to 80 Years
- Results posted
- No results posted in this snapshot
- Countries
- China
- Total sites listed
- 4
Eligibility criteria
Show eligibility criteria (verbatim from the registry)
Inclusion Criteria: * Clinical diagnosis of coronary artery disease; * Signed informed consent. Exclusion Criteria: * Obvious aortic insufficiency; * Aortic aneurysm; * Aortic dissection; * Coronary fistula or severe coronary aneurysm; * Symptomatic Congestive heart failure; * Valvular heart disease; * Congenital heart diseases; * Cardiomyopathies * Cerebral hemorrhage within six months; * Uncontrolled hypertension, defined as SBP≥180mmHg or DBP≥110mmHg; * Lower limb infection; * Deep venous thrombosis; * Progressive malignancies
Source: ClinicalTrials.gov (US National Library of Medicine), snapshot October 2026. Check the registry for current recruiting status. Record: https://clinicaltrials.gov/study/NCT03075124